BioAge Labs, Inc. (BIOA)

In the past six months, BioAge Labs, Inc. stock has been impacted by several key events. Citi upgraded BioAge Labs from Neutral to Buy and increased its price target from $5 to $10, citing optimism regarding BGE-102's potential in obesity treatment, contributing to a significant stock increase. BioAge Labs filed for an offering of up to 2.23 million shares by selling stockholders. The company announced the dosing of the first participant in a Phase 1 clinical trial for BGE-102. BioAge Labs reported its second-quarter 2025 financial results, with revenue reaching $2.4 million. The company also announced its participation in upcoming investor conferences.

As a clinical-stage biopharmaceutical company, BioAge Labs, Inc. does not currently have commercialized products, so there is no traditional demand seasonality for its products or services. The company's revenue generation is primarily tied to research and development activities, partnerships, and potential future licensing agreements, rather than seasonal consumer demand.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, operating within the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations and Medical - Biomedical and Genetics industries. The company utilizes a proprietary technology platform that integrates machine learning, omics data, and human datasets to identify molecular changes that drive aging and inform target identification for drug development, with a primary focus on metabolic diseases, including obesity. Its major product candidates include Azelaprag, an orally available small molecule in Phase 1 clinical trial for obesity, with a Phase 2 trial initiated in combination with tirzepatide for obesity in older adults, and BGE-102, an orally available, brain-penetrant NLRP3 antagonist in Phase 1 development for diseases driven by neuroinflammation, with potential applications in obesity.

BioAge Labs, Inc. is headquartered in Richmond, California, United States.

In the past year, BioAge Labs' brand reputation has been influenced by several events. The upgrade to a "Buy" rating and increased price target from Citi reflects positive analyst sentiment. The initiation of a Phase 1 clinical trial for BGE-102 is a positive development. The company reported promising preclinical results for an APJ Agonist, which could enhance its reputation. BioAge Labs launched an initiative to analyze over 17,000 HUNT Biobank samples for drug discovery in aging-related diseases. The company successfully raised $170 million in an oversubscribed Series D financing round, indicating strong investor confidence. The discontinuation of an in-licensed obesity drug candidate due to a safety signal could have negatively impacted its reputation.

BioAge Labs, Inc. has significant institutional ownership, with institutions holding between 46% and 57.79% of the company's shares. Major institutional owners include AH Capital Management, L.L.C., Sofinnova Investments, Inc., Cormorant Asset Management, LP, ADAR1 Capital Management, LLC, Tang Capital Management Llc, Vanguard Group Inc, BlackRock, Inc., Orbimed Advisors Llc, Sands Capital Ventures, LLC, RA Capital Management, L.P., Khosla Ventures VI, L.P., and Longitude Capital Management Co., LLC. Vijay Satyanand Pande is the largest individual shareholder, owning 9.02% of the company's shares, and CEO Kristen Fortney holds a 3.4% stake.